Toll-like receptor signaling pathway components (TLR signaling pathway)

The Toll signaling pathway is a fundamental axis of the innate immune system, centered on Toll-like receptors (TLRs) that detect conserved microbial structures and endogenous danger signals (Takeda K, Akira S. Toll-like receptors. Curr Protoc Immunol. 2015) [1]. Activation of these components initiates a complex signaling architecture involving adaptor proteins like MyD88 and TRIF, which coordinate the activation of kinases such as IRAK4 and IKK (Gay NJ, et al. Assembly and localization of Toll-like receptor signalling complexes. Nat Rev Immunol. 2014) [2]. This process culminates in the nuclear translocation of NF-kappaB and IRF transcription factors, driving the production of inflammatory cytokines and interferons essential for host defense (Kawasaki T, Kawai T. Toll-like receptor signaling pathways. Front Immunol. 2014) [3]. In clinical contexts, overactivation of this pathway contributes to the pathogenesis of sepsis, rheumatoid arthritis, and systemic lupus erythematosus, while its suppression can facilitate tumor immune evasion (Nie L, et al. Toll-like receptors as therapeutic targets for autoimmune diseases and cancer. Expert Opin Ther Targets. 2016) [4]. Therapeutic strategies targeting this pathway include TLR agonists used as potent vaccine adjuvants and anti-tumor agents, as well as small molecule inhibitors and antibodies designed to dampen pathological inflammation (Hennessy EJ, et al. Targeting Toll-like receptors: emerging therapeutics? Nat Rev Drug Discov. 2010) [5].

Other names

Toll pathwayToll-like receptor signalingTLR signaling cascadeInnate immune signaling pathwayMyD88-dependent pathwayTRIF-dependent pathway

Agonism of Toll-like receptors (TLRs) to stimulate innate and adaptive immune responses for use in vaccines and oncology; Antagonism of TLRs or inhibition of downstream signaling components (e.g., IRAK4) to suppress pathological inflammation in autoimmune and autoinflammatory diseases.